ICORG’s contribution to the development of an important new drug (PD 0332991) has been recognised in an oral presentation to be given at the San Antonio Breast Cancer Symposium in December 2012.
Dr Janice Walshe is ICORG’s Chief Investigator for this study which is a Phase 1/2, open-label, randomized study of the safety, efficacy and pharmacokinetics of letrozole plus PD 0332991 (Oral CDK 4/6 Inhibitor) and letrozole single agent for the first-line Treatment of ER positive, HER2 negative Advanced Breast Cancer in postmenopausal women.
Four Hospital Sites in Ireland participated in this Global Study.